Role of the lysophosphatidylinositol/GPR55 axis in cancer

Advances in Biological Regulation

Volumn 60, Issue , 2016, Pages 88-93

  Falasca, Marco ^a,b   Ferro, Riccardo ^b  

^a CURTIN UNIVERSITY   (Australia)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ABC transporters; Cancer; Cannabidiol; G protein coupled receptor 55; LPI

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GPR55 PROTEIN, HUMAN; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHOLIPID;

ANIMAL; CARCINOGENESIS; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; HUMANS; LYSOPHOSPHOLIPIDS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84958778421     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2015.10.003     Document Type: Review

References (42)

1. Andradas C., Caffarel M.M., Perez-Gomez E., Salazar M., Lorente M., Velasco G., et al. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 2011, 30:245-252.
2. Aviello G., Romano B., Borrelli F., Capasso R., Gallo L., Piscitelli F., et al. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J. Mol. Med. 2012, 90:925-934.
3. Baker D., Pryce G., Davies W.L., Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 2006, 27:1-4.
4. De Petrocellis L., Ligresti A., Moriello A.S., Allara M., Bisogno T., Petrosino S., et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 2011, 163:1479-1494.
5. Falasca M., Corda D. Elevated levels and mitogenic activity of lysophosphatidylinositol in k-ras-transformed epithelial cells. Eur. J. Biochem. FEBS 1994, 221:383-389.
6. Falasca M., Silletta M.G., Carvelli A., Di Francesco A.L., Fusco A., Ramakrishna V., et al. Signalling pathways involved in the mitogenic action of lysophosphatidylinositol. Oncogene 1995, 10:2113-2124.
7. Falasca M., Iurisci C., Carvelli A., Sacchetti A., Corda D. Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation. Oncogene 1998, 7:2357-2365.
8. Fitzgerald T.L., Lertpiriyapong K., Cocco L., Martelli A.M., Libra M., Candido S., et al. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Adv. Biol. Regul. September 2015, 59:65-81.
9. Ford L.A., Roelofs A.J., Anavi-Goffer S., Mowat L., Simpson D.G., Irving A.J., et al. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br. J. Pharmacol. 2010, 160:762-771.
10. Hausmann J., Perrakis A., Moolenaar W.H. Structure-function relationships of autotaxin, a secreted lysophospholipase D. Adv. Biol. Regul. 2013, 53:112-117.
11. He D., Wang J., Zhang C., Shan B., Deng X., Li B., et al. Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Mol. Cancer 2015, 14:73.
12. Henstridge C.M., Balenga N.A., Ford L.A., Ross R.A., Waldhoer M., Irving A.J. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2009, 23:183-193.
13. Henstridge C.M., Balenga N.A., Schroder R., Kargl J.K., Platzer W., Martini L., et al. GPR55 ligands promote receptor coupling to multiple signalling pathways. Br. J. Pharmacol. 2010, 160:604-614.
14. Heynen-Genel S., Dahl R., Shi S., Milan L., Hariharan S., Sergienko E., et al. Screening for selective ligands for GPR55-antagonists. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD) 2010.
15. Hofmann N.A., Yang J., Trauger S.A., Nakayama H., Huang L., Strunk D., et al. The GPR 55 agonist, L-alpha-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis. Br. J. Pharmacol. 2015, 172:4107-4118.
16. Kargl J., Brown A.J., Andersen L., Dorn G., Schicho R., Waldhoer M., et al. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J. Pharmacol. Exp. Ther. 2013, 346:54-66.
17. Kathmann M., Flau K., Redmer A., Trankle C., Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 2006, 372:354-361.
18. Keenan R.W., Hokin L.E. The identification of lysophosphatidylinositol and its enzymic conversion to phosphatidylinositol. Biochim. Biophys. Acta 1962, 60:428-430.
19. Kotsikorou E., Sharir H., Shore D.M., Hurst D.P., Lynch D.L., Madrigal K.E., et al. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 2013, 52:9456-9469.
20. Lauckner J.E., Jensen J.B., Chen H.Y., Lu H.C., Hille B., Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2699-2704.
21. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 2006, 318:1375-1387.
22. Massi P., Vaccani A., Ceruti S., Colombo A., Abbracchio M.P., Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J. Pharmacol. Exp. Ther. 2004, 308:838-845.
23. McAllister S.D., Christian R.T., Horowitz M.P., Garcia A., Desprez P.Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol. Cancer Ther. 2007, 6:2921-2927.
24. McCubrey J.A., Davis N.M., Abrams S.L., Montalto G., Cervello M., Libra M., et al. Targeting breast cancer initiating cells: advances in breast cancer research and therapy. Adv. Biol. Regul. 2014, 56:81-107.
25. Metz S.A. Lysophosphatidylinositol, but not lysophosphatidic acid, stimulates insulin release. A possible role for phospholipase A2 but not de novo synthesis of lysophospholipid in pancreatic islet function. Biochem. Biophys. Res. Commun. 1986, 138:720-727.
26. Mikoshiba K. Role of IP3 receptor signaling in cell functions and diseases. Adv. Biol. Regul. 2015, 57:217-227.
27. Nagahashi M., Hait N.C., Maceyka M., Avni D., Takabe K., Milstien S., et al. Sphingosine-1-phosphate in chronic intestinal inflammation and cancer. Adv. Biol. Regul. 2014, 54:112-120.
28. Oka S., Kimura S., Toshida T., Ota R., Yamashita A., Sugiura T. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J. Biochem. 2010, 147:671-678.
29. Oka S., Nakajima K., Yamashita A., Kishimoto S., Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 2007, 362:928-934.
30. Perez-Gomez E., Andradas C., Flores J.M., Quintanilla M., Paramio J.M., Guzman M., et al. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene 2013, 32:2534-2542.
31. Pineiro R., Maffucci T., Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 2011, 30:142-152.
32. Piñeiro R., Falasca M. Lysophosphatidylinositol signalling: new wine from an old bottle. Biochim. Biophys. Acta 2012, 182:694-705.
33. Ramer R., Merkord J., Rohde H., Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem. Pharmacol. 2010, 79:955-966.
34. Rempel V., Volz N., Glaser F., Nieger M., Brase S., Muller C.E. Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. J. Med. Chem. 2013, 56:4798-4810.
35. Ross R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 2009, 30:156-163.
36. Russo E.B., Burnett A., Hall B., Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 2005, 30:1037-1043.
37. Sawzdargo M., Nguyen T., Lee D.K., Lynch K.R., Cheng R., Heng H.H., et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res. 1999, 64:193-198.
38. Stancic A., Jandl K., Hasenohrl C., Reichmann F., Marsche G., Schuligoi R., et al. The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 2015.
39. Sutphen R., Xu Y., Wilbanks G.D., Fiorica J., Grendys E.C., LaPolla J.P., et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 2004, 13:1185-1191.
40. Thomas A., Baillie G.L., Phillips A.M., Razdan R.K., Ross R.A., Pertwee R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 2007, 150:613-623.
41. Xiao Y., Chen Y., Kennedy A.W., Belinson J., Xu Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann. N. Y. Acad. Sci. 2000, 905:242-259.
42. Yamashita A., Oka S., Tanikawa T., Hayashi Y., Nemoto-Sasaki Y., Sugiura T. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55. Prostaglandins Other Lipid Mediat. 2013, 107:103-116.